Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males

被引:0
作者
Jin Wang
Lu Qi
Zejuan Wang
Gang Chen
Chen Liu
Ying Liu
Xiaona Liu
Yu Wang
Chunpu Lei
Xinghe Wang
机构
[1] Capital Medical University,Phase I Clinical Centre, Beijing Shijitan Hospital
来源
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词
Lenalidomide; Revlimid; Pharmacokinetics; Bioequivalence; LS-MS/MS;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:159 / 164
页数:5
相关论文
共 60 条
[1]  
Gupta D(2001)Adherence of multiple myeloma cells to bone marrow stromal cells up regulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 15 1950-1961
[2]  
Treon SP(2003)Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia 17 41-44
[3]  
Shima Y(2002)Apoptosis signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 99 4525-4530
[4]  
Lentzsch S(2015)Expanding role of lenalidomide in hematologic malignancies Cancer Manag Res 7 105-119
[5]  
LeBlanc R(2005)Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549-557
[6]  
Podar K(2007)The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes Curr Opin Hematol 14 123-129
[7]  
Mitsiades N(2006)A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma Blood 108 3458-3464
[8]  
Mitsiades CS(2010)Distribution of lenalidomide into semen of healthy men after multiple oral doses J Clin Pharmacol 50 767-774
[9]  
Poulaki V(2014)Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care Lancet Oncol 15 e112-e118
[10]  
Ghosh N(2015)Pricing in the market for anticancer drugs J Econ Perspect 29 139-162